Tempus AI Faces Growth Tailwinds but GAAP Losses and Execution Risks Persist

Earnings
โดย Zacks Investment Research·Read original
Summary · why it matters

Tempus AI is well positioned for growth driven by diagnostics volume increases and expanding data partnerships, but large GAAP losses and multi-thread execution demands may sustain volatility for investors. In the first quarter of 2026, diagnostics revenues rose 34.7% year over year, with Oncology volume up 28% and Hereditary volume up 54%, while Data and Applications revenues grew 40.5% to $87 million, supported by a new multi-year collaboration with Merck and an expanded Lens agreement with Gilead. However, the company reported a net loss of $125.9 million, including $56.3 million in stock-based compensation and related payroll taxes and $32.3 million in unrealized losses on marketable securities. Management noted that hereditary growth slowed as comps normalized and expects a return to mid-teens growth later in the year, while MRD reimbursement remains in early rollout. The Zacks Consensus Estimate for 2026 revenues is $1.59 billion, implying 25.2% growth, and the loss per share estimate has widened by one cent to 34 cents over the past 30 days.

Impact on stocks 7

Biotech & Genomic Medicine▲ · 3 stocks
Artificial Intelligence▲ · 1 stocks
Tempus AI, Inc. Class A Common Stock
TEM
▲ PositiveDemandCapitalrelevance

Diagnostics revenues rose 34.7% YoY, with Oncology volume up 28% and Hereditary volume up 54%, and Data revenues grew 40.5% with new Merck collaboration and expanded Gilead agreement.

Robotics & Physical AI▲ · 1 stocks
Critical Materials & Supply Chain▲ · 1 stocks
Health Care▲ · 1 stocks
© 2026 MarketDXNews